Significantly more patients with acute migraine who received a 10 L per minute dose of a transnasal cooling device had pain freedom at 2 hours vs. those who received sham, according to research ...

Monash University scientists have developed a new (preclinical) method to distinguish between chronic pain subtypes, such as ...

When doing knee exercises, start with a few reps and move up gradually. If you have pain with any movement, stop. If your exercise program makes you too sore to move the next day, you are ...

New devices promise relief from period pain, headaches, neck and back problems and muscle pains without the use of drugs. Here, we look at some more gadgets that might help you break away from the ...

Medtronic's recall of embolization device has been classified most serious by the U.S. Food and Drug Administration (USFDA), citing potential risks of severe injury or death. This decision follows the ...

TriCare, the federal health insurer for the military, has temporarily stopped paying the medical claims of pain management device maker Zynex Medical. In a recent filing with the Securities and ...

Bengaluru: The U.S. Food and Drug Administration on Tuesday classified the recall of Medtronic's embolization device as "most serious", following reports of the deaths of four patients.

The Food and Drug Administration has identified a Class I recall of Medtronic Neurovascular 027 Compatible Pipeline Vantage Embolization Devices due to reports of a higher incidence of the flexible, ...

Medtronic has recalled embolization devices collectively linked to reports of 17 injuries and four deaths, the Food and Drug Administration said Tuesday. The recall has two elements: Medtronic is ...

Medtronic has recalled certain Pipeline Vantage Embolization Devices with Shield Technology due to an increased risk of incomplete wall apposition and braid deformation, which could lead to stroke ...

Medtronic’s recalled devices are used for brain aneurysm treatment. The estimated prevalence of unruptured intracranial aneurysms (UIAs) in the general population is around 3.2%, with an annual risk ...